OR10-05 Improved Mental And Psychosocial Patient-Reported Outcomes Among People With Obesity Treated With Tirzepatide: Results From SURMOUNT-1 Study

por Poon, Jiat Ling, Zhang, Shuyu, Kan, Hong, Bunck, Mathijs C, Dunn, Julia, Stefanski, Adam, Murphy, Madhumita
Publicado 2023

SAT660 Predictors Of Achieving Body Weight Reduction ≥20% With Tirzepatide In People With Overweight Or Obesity In SURMOUNT-1

por Srinath, Reshmi, Pedersen, Sue, Neff, Lisa, Cao, Dachuang, Kao, Christi Y, Stefanski, Adam, Ahmad, Nadia, Eun Lee, Clare Jung
Publicado 2023

The Common C49620T Polymorphism in the Sulfonylurea Receptor Gene SUR1 (ABCC8) in Patients with Gestational Diabetes and Subsequent Glucose Metabolism Abnormalities

por Molęda, Piotr, Bińczak-Kuleta, Agnieszka, Homa, Katarzyna, Safranow, Krzysztof, Celewicz, Zbigniew, Syrenicz, Anhelli, Stefański, Adam, Fronczyk, Aneta, Majkowska, Lilianna
Publicado 2012

SAT658 Tirzepatide Reduces The Predicted Risk Of Developing Atherosclerotic Cardiovascular Disease: A Post-hoc Analysis Of The Surmount-1 Trial

por Hankosky, Emily R, Wang, Hui, Lisa, Neff M, Kan, Hongjun, Wang, Fangyu, Ahmad, Nadia N, Stefanski, Adam, Timothy Garvey, W
Publicado 2023